John Garner

mPEG-PCL from PolySciTech used in development of oral pancreatic cancer therapy

Blog Post created by John Garner on Dec 7, 2018

Youssef, 2018 PEG-PCL flutamide.jpg

There are many medicinal compounds which are clinically effective but lack adequate oral bioavailability. Low bioavailability can be overcome through a variety of formulatory approaches. Recently, researchers at Alexandria University used mPEG-PCL (AK105) from PolySciTech ( to develop polymersomes with improved bioavailability. This research holds promise for improved therapy of pancreatic cancer. Read more: Youssef, Shams F., Yosra SR Elnaggar, and Ossama Y. Abdallah. "Elaboration of polymersomes versus conventional liposomes for improving oral bioavailability of the anticancer flutamide." Nanomedicine 00 (2018).


“Aim: Flutamide is an outstanding anticancer drug with poor oral bioavailability. This is the first work to investigate the potential of polymersomes versus conventional liposomes to improve flutamide bioavailability. Materials & methods: Polymersomes were prepared by solvent-switching technique and successfully optimized with excellent nanometric size (143 nm) and ζ-potential (-33.4 mV). Physicochemical characterization, stability in gastrointestinal tract and in vivo oral pharmacokinetics in male Sprague–Dawely rats were performed. Results: A significantly higher stability in simulated intestinal fluid was demonstrated by polymersomes compared with liposomes. Great improvement in flutamide oral bioavailability in polymersomes compared with both liposomes and drug suspension was obtained. Conclusion: Polymersomes are promising nanoplatforms to overcome stability problems of liposomes and to improve flutamide oral bioavailability. Keywords:flutamide liposomes oral bioavailability pharmacokinetics polymersomes prostate cancer”